Outcomes and progression predictors in a New Zealand active surveillance programme for prostate cancer.
[OBJECTIVE] To describe outcomes and identify predictors of histological progression in men on active surveillance (AS) for International Society of Urological Pathology Grade Group (ISUP GG) 1 prosta
APA
Xu K, Shah N, et al. (2026). Outcomes and progression predictors in a New Zealand active surveillance programme for prostate cancer.. BJU international. https://doi.org/10.1111/bju.70276
MLA
Xu K, et al.. "Outcomes and progression predictors in a New Zealand active surveillance programme for prostate cancer.." BJU international, 2026.
PMID
41983272
Abstract
[OBJECTIVE] To describe outcomes and identify predictors of histological progression in men on active surveillance (AS) for International Society of Urological Pathology Grade Group (ISUP GG) 1 prostate cancer in New Zealand (NZ), as AS is the standard management for favourable-risk prostate cancer, yet NZ-specific outcome data remain limited.
[PATIENTS AND METHODS] A retrospective study of the North Shore Hospital AS programme (2014-2020) was conducted. Records were reviewed in 2024. In total, 296 men with ISUP GG 1 disease on AS were included. Primary endpoints were histological progression to ISUP GG ≥2, treatment conversion, and disease-related mortality.
[RESULTS] Over a mean 7.4-year follow-up, 36.5% progressed, 33.4% required treatment, 12.1% recurred after treatment, and one patient died from metastatic disease. Within the cohort, a low-risk subgroup of 93 patients with ISUP GG 1 prostate cancer had low prostate-specific antigen (PSA) density and no suspicious magnetic resonance imaging (MRI) lesions. Of these patients, 16 (17.2%) progressed. On multivariate analysis, independent predictors of progression were PSA density ≥0.15 ng/mL/mL (odds ratio [OR] 3.45) and Prostate Imaging-Reporting and Data System 3-5 lesions (OR 3.52).
[CONCLUSION] Active surveillance is a safe option for low-risk prostate cancer, our data are consistent with outcomes consistent with the Prostate Cancer Outcomes Registry and international data. PSA density and multiparametric MRI were the strongest predictors of progression; tumour volume by percentage of positive cores was not independently predictive. New draft Prostate Cancer Foundation of Australia guidelines recommend against biopsy in men with PSA density <0.15 ng/mL/cc and no PIRADS 3-5 lesion on MRI[7], in our cohort this included many men with ISUP 1 cancer. They had a 17.2% progression rate to ISUP ≥2, and their clinically significant disease might have been missed without close surveillance.
[PATIENTS AND METHODS] A retrospective study of the North Shore Hospital AS programme (2014-2020) was conducted. Records were reviewed in 2024. In total, 296 men with ISUP GG 1 disease on AS were included. Primary endpoints were histological progression to ISUP GG ≥2, treatment conversion, and disease-related mortality.
[RESULTS] Over a mean 7.4-year follow-up, 36.5% progressed, 33.4% required treatment, 12.1% recurred after treatment, and one patient died from metastatic disease. Within the cohort, a low-risk subgroup of 93 patients with ISUP GG 1 prostate cancer had low prostate-specific antigen (PSA) density and no suspicious magnetic resonance imaging (MRI) lesions. Of these patients, 16 (17.2%) progressed. On multivariate analysis, independent predictors of progression were PSA density ≥0.15 ng/mL/mL (odds ratio [OR] 3.45) and Prostate Imaging-Reporting and Data System 3-5 lesions (OR 3.52).
[CONCLUSION] Active surveillance is a safe option for low-risk prostate cancer, our data are consistent with outcomes consistent with the Prostate Cancer Outcomes Registry and international data. PSA density and multiparametric MRI were the strongest predictors of progression; tumour volume by percentage of positive cores was not independently predictive. New draft Prostate Cancer Foundation of Australia guidelines recommend against biopsy in men with PSA density <0.15 ng/mL/cc and no PIRADS 3-5 lesion on MRI[7], in our cohort this included many men with ISUP 1 cancer. They had a 17.2% progression rate to ISUP ≥2, and their clinically significant disease might have been missed without close surveillance.
같은 제1저자의 인용 많은 논문 (5)
- Coexistence of a primary ALK-positive and MET14 exon skipping mutation double-fusion in one patient with NSCLC and response to crizotinib: A case report and literature review.
- Genetic evidence supporting obesity as a risk factor for lung squamous cell carcinoma and the identification of MFAP1 as a shared genetic target.
- The application of 3D cell culture for melanoma in vitro models.
- Pseudoginsenoside F11 enhances YBX1-mediated transcriptional repression of PRPS2 to inhibit the stemness and pulmonary metastasis of triple- negative breast cancer.
- AF6 knockout-induced upregulation of bile acid production promotes CXCL14-mediated antitumor immunity in HCC.